FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2027367341> ?p ?o ?g. }

• W2027367341 abstract "The Evaluate Patient OutComes (EPOC) study assessed physician- and patient-reported outcomes in individuals with relapsing multiple sclerosis who switched directly from injectable disease-modifying therapy (iDMT; glatiramer acetate, intramuscular or subcutaneous interferon beta-1a, or interferon beta-1b) to once-daily, oral fingolimod. Post hoc analyses evaluated the impact of a switch to fingolimod versus staying on each of the four individual iDMTs.Overall, 1053 patients were randomized 3:1 to switch to fingolimod or remain on iDMT. The primary endpoint was the change in Treatment Satisfaction Questionnaire for Medication (TSQM) Global Satisfaction score. Secondary endpoints included changes in scores for TSQM Effectiveness, Side Effects and Convenience subscales, Beck Depression Inventory-II (BDI-II), Fatigue Severity Scale (FSS), Patient-Reported Outcome Indices for Multiple Sclerosis (PRIMUS) Activities, 36-item Short-Form Health Survey (SF-36) Mental Component Summary (MCS) and Physical Component Summary (PCS) and mean investigator-reported Clinical Global Impressions of Improvement (CGI-I). All outcomes were evaluated after 6 months of treatment.Changes in TSQM Global Satisfaction scores were superior after a switch to fingolimod when compared with scores in patients remaining on any of the iDMTs (all p <0.001). Likewise, all TSQM subscale scores improved following a switch to fingolimod (all p <0.001), except when compared with glatiramer acetate for the TSQM Side Effects subscale (p = 0.111). FSS scores were found to be superior for fingolimod versus remaining on subcutaneous interferon beta-1a and interferon beta-1b, BDI-II scores were significantly improved for fingolimod except for the comparison with intramuscular interferon beta-1a, and SF-36 scores were superior with fingolimod compared with remaining on interferon beta-1b (MCS and PCS; p = 0.030 and p = 0.022, respectively) and subcutaneous interferon beta-1a (PCS only; p = 0.024). Mean CGI-I scores were superior with fingolimod when compared with continuing treatment with any of the iDMTs (all p <0.001).After 6 months, a switch to fingolimod showed superiority compared with remaining on each iDMT for a range of patient- and physician-reported outcomes, including global satisfaction with treatment.ClinicalTrials.gov NCT01216072 ." @default.
• W2027367341 created "2016-06-24" @default.
• W2027367341 creator A5004241893 @default.
• W2027367341 creator A5018430300 @default.
• W2027367341 creator A5020903163 @default.
• W2027367341 creator A5021092696 @default.
• W2027367341 creator A5048656035 @default.
• W2027367341 creator A5054870186 @default.
• W2027367341 creator A5063096714 @default.
• W2027367341 creator A5063965210 @default.
• W2027367341 creator A5064338988 @default.
• W2027367341 creator A5084593189 @default.
• W2027367341 creator A5086981214 @default.
• W2027367341 date "2014-11-26" @default.
• W2027367341 modified "2023-10-14" @default.
• W2027367341 title "Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient- and physician-reported outcomes in relapsing multiple sclerosis: post hocanalyses of the EPOC trial" @default.
• W2027367341 cites W155259919 @default.
• W2027367341 cites W1977994425 @default.
• W2027367341 cites W1984207232 @default.
• W2027367341 cites W1986991730 @default.
• W2027367341 cites W2000889227 @default.
• W2027367341 cites W2008872064 @default.
• W2027367341 cites W2011932878 @default.
• W2027367341 cites W2025177594 @default.
• W2027367341 cites W2029412737 @default.
• W2027367341 cites W2030843522 @default.
• W2027367341 cites W2037377025 @default.
• W2027367341 cites W2049871497 @default.
• W2027367341 cites W2052847251 @default.
• W2027367341 cites W2082301205 @default.
• W2027367341 cites W2082428529 @default.
• W2027367341 cites W2089796211 @default.
• W2027367341 cites W2104948944 @default.
• W2027367341 cites W2106020444 @default.
• W2027367341 cites W2109158135 @default.
• W2027367341 cites W2113291839 @default.
• W2027367341 cites W2114242035 @default.
• W2027367341 cites W2114780052 @default.
• W2027367341 cites W2133392888 @default.
• W2027367341 cites W2134033939 @default.
• W2027367341 cites W2138834872 @default.
• W2027367341 cites W2144317224 @default.
• W2027367341 cites W2148520799 @default.
• W2027367341 cites W2151340435 @default.
• W2027367341 cites W2151630317 @default.
• W2027367341 cites W2154936683 @default.
• W2027367341 cites W2156272881 @default.
• W2027367341 cites W2162821925 @default.
• W2027367341 cites W2167876561 @default.
• W2027367341 cites W2169398435 @default.
• W2027367341 cites W2169569625 @default.
• W2027367341 cites W2170689912 @default.
• W2027367341 cites W24020054 @default.
• W2027367341 cites W2704729794 @default.
• W2027367341 cites W2916040650 @default.
• W2027367341 cites W4214559180 @default.
• W2027367341 cites W4292806894 @default.
• W2027367341 doi "https://doi.org/10.1186/s12883-014-0220-1" @default.
• W2027367341 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4253981" @default.
• W2027367341 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25424122" @default.
• W2027367341 hasPublicationYear "2014" @default.
• W2027367341 type Work @default.
• W2027367341 sameAs 2027367341 @default.
• W2027367341 citedByCount "27" @default.
• W2027367341 countsByYear W20273673412016 @default.
• W2027367341 countsByYear W20273673412017 @default.
• W2027367341 countsByYear W20273673412018 @default.
• W2027367341 countsByYear W20273673412019 @default.
• W2027367341 countsByYear W20273673412020 @default.
• W2027367341 countsByYear W20273673412021 @default.
• W2027367341 countsByYear W20273673412022 @default.
• W2027367341 countsByYear W20273673412023 @default.
• W2027367341 crossrefType "journal-article" @default.
• W2027367341 hasAuthorship W2027367341A5004241893 @default.
• W2027367341 hasAuthorship W2027367341A5018430300 @default.
• W2027367341 hasAuthorship W2027367341A5020903163 @default.
• W2027367341 hasAuthorship W2027367341A5021092696 @default.
• W2027367341 hasAuthorship W2027367341A5048656035 @default.
• W2027367341 hasAuthorship W2027367341A5054870186 @default.
• W2027367341 hasAuthorship W2027367341A5063096714 @default.
• W2027367341 hasAuthorship W2027367341A5063965210 @default.
• W2027367341 hasAuthorship W2027367341A5064338988 @default.
• W2027367341 hasAuthorship W2027367341A5084593189 @default.
• W2027367341 hasAuthorship W2027367341A5086981214 @default.
• W2027367341 hasBestOaLocation W20273673411 @default.
• W2027367341 hasConcept C118552586 @default.
• W2027367341 hasConcept C126322002 @default.
• W2027367341 hasConcept C141071460 @default.
• W2027367341 hasConcept C1862650 @default.
• W2027367341 hasConcept C2775944032 @default.
• W2027367341 hasConcept C2776036978 @default.
• W2027367341 hasConcept C2778577042 @default.
• W2027367341 hasConcept C2779134260 @default.
• W2027367341 hasConcept C2780640218 @default.
• W2027367341 hasConcept C2908698914 @default.
• W2027367341 hasConcept C2994247566 @default.
• W2027367341 hasConcept C71924100 @default.
• W2027367341 hasConceptScore W2027367341C118552586 @default.
• W2027367341 hasConceptScore W2027367341C126322002 @default.
• W2027367341 hasConceptScore W2027367341C141071460 @default.

• next